To evaluate the in vivo therapeutic potential of anti-TNFR2 therapy, BALB/c mice were subcutaneously injected with 4T1 tumor cells on the right flank, and once tumor size reached 50–100 mm3, animals were randomly divided into two groups (n = 6 in each group): treatment group with anti-TNFR2 antibody intraperitoneally (i.p.)injection every 3 days and control group with IgG isotype intraperitoneally (i.p.)injection every 3 days. This evidence concerns the gene TNFRSF1B and neoplasm.